410 related articles for article (PubMed ID: 20664988)
1. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
Jang K; Kim M; Seo HS; Shin I
Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
3. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
4. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling.
Hayashi H; Tsuchiya Y; Nakayama K; Satoh T; Nishida E
Genes Cells; 2008 Sep; 13(9):941-7. PubMed ID: 18691227
[TBL] [Abstract][Full Text] [Related]
6. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
[TBL] [Abstract][Full Text] [Related]
7. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
Fukazawa H; Noguchi K; Murakami Y; Uehara Y
Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
[TBL] [Abstract][Full Text] [Related]
8. PAR2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathways in GI epithelial cells.
Tanaka Y; Sekiguchi F; Hong H; Kawabata A
Biochem Biophys Res Commun; 2008 Dec; 377(2):622-626. PubMed ID: 18854173
[TBL] [Abstract][Full Text] [Related]
9. [Cross-talk between PI3K/Akt and MEK/ERK pathways regulates human hepatocellular carcinoma cell cycle progression under endoplasmic reticulum stress].
Yan DM; Dai RY; Duan CY; Chen SK; Liu YP; Chen CN; Li H
Zhonghua Gan Zang Bing Za Zhi; 2010 Dec; 18(12):909-14. PubMed ID: 21205476
[TBL] [Abstract][Full Text] [Related]
10. [Overexpression of HER2/neu downregulates wild p53 protein expression via PI3K and Ras/Raf/MEK/ERK pathways in human breast cancer cells].
Zheng L; Ren JQ; Zhang L; Chen Q; Zhu HG
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):358-62. PubMed ID: 15363324
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
12. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells.
Squires MS; Hudson EA; Howells L; Sale S; Houghton CE; Jones JL; Fox LH; Dickens M; Prigent SA; Manson MM
Biochem Pharmacol; 2003 Feb; 65(3):361-76. PubMed ID: 12527329
[TBL] [Abstract][Full Text] [Related]
13. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways.
Hagemeister AL; Sheridan MA
Am J Physiol Regul Integr Comp Physiol; 2008 Aug; 295(2):R490-7. PubMed ID: 18495839
[TBL] [Abstract][Full Text] [Related]
15. PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.
Ren Y; Zhou X; Qi Y; Li G; Mei M; Yao Z
Oncol Rep; 2012 Sep; 28(3):943-8. PubMed ID: 22710837
[TBL] [Abstract][Full Text] [Related]
16. Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231).
Elumalai P; Arunkumar R; Benson CS; Sharmila G; Arunakaran J
Cell Biochem Funct; 2014 Jul; 32(5):476-84. PubMed ID: 24888707
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
18. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways.
Lu H; Jiang T; Ren K; Li ZL; Ren J; Wu G; Han X
Cell Physiol Biochem; 2018; 49(1):217-225. PubMed ID: 30138923
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
20. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
